Sherri Borman

Sherri Borman has served as Executive Laboratory Director since June 2021, previously serving as Castle’s Laboratory Director from October 2018 – May 2021. Dr. Borman is a multidisciplinary diagnostics leader with significant experience teaching in academic institutions and leading commercial operations in clinical laboratories. With over 20 years of experience, she leads CAP-accredited, New York State-Approved, CLIA-certified high throughput, molecular clinical, and research laboratories. She has been successful in scaling laboratory operations and building experienced, highly motivated teams to meet the demands of a high-growth environment.

Prior to joining Castle, Dr. Borman served as Laboratory Director in two other clinical diagnostic laboratories, as well as Vice President of Laboratory Operations. She has contributed to the development and validation of several new laboratory-developed tests (LDT) in cancers over the course of her career and has co-authored multiple scientific publications.

Dr. Borman holds a B.S. in nutritional sciences, with a minor in chemistry, and a Ph.D. in physiological sciences, with a minor in cell biology, anatomy, and toxicology, from the University of Arizona. She also completed an NIH Post-Doctoral Fellowship at Oregon Health & Science University. Dr. Borman is board certified, through the American Board of Bioanalysis, as a high-complexity clinical laboratory director and clinical consultant, and as a New York state-certified laboratory director with several state licenses.